News (EN) // 

CONGEN offers 1.5 millionen SARS-CoV-2 analyzes

As one of the first manufactures CONGEN designed a molecular test kit for the detection of SARS-CoV-2 . This method enables the qualitative and specific detection of SARS-CoV-2 RNA from human respiratory samples. Until the first development, CONGEN expanded the production capacities, continuously. So far, CONGEN offered more than 1.5 million analyzes for the health system.

The global non-profit organization FIND (Foundation for Innovative New Diagnostica), a WHO Collaborating Centre, published independent evaluations of SARS-COV 2 molecular assays.  All selected assays were compared regarding Limit of Detection (LOD), clinical sensitivity and clinical specificity. The result of the evaluation confirmend that the RIDA® GENE SARS-CoV-2 RUO assay distributed by R-Biopharm, is specific and sensitive with a LOD 1-10 copies.

More details about the evaluations:

Regarding food safety, CONGEN offers a fast and specific solution for swab samples. The SureFast® Speed PREP in combination with the real-time assay SureFast® SARS-CoV-2  PLUS, enables customers to screen for SARS-CoV-2. If you need more information, please send an email.